CAP Partners’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$310K Buy
5,596
+380
+7% +$20.5K 0.14% 124
2026
Q2
$284K Buy
5,216
+915
+21% +$48.2K 0.14% 133
2026
Q1
$205K Buy
+4,301
New +$227K 0.12% 144

Other funds holding CRSP

CAP Partners's CRSP Position: Q3 2026 in Review

CAP Partners increased its CRISPR Therapeutics (CRSP) stake by 7.3% in Q3 2026, buying an estimated $20.5K and bringing the position to 5,596 shares worth $310K. The position accounts for 0.14% of the portfolio, ranked #124.

CAP Partners first reported a position in CRSP in Q1 2026 and has held it in 3 quarters since. 413 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • CAP Partners held 5,596 shares of CRISPR Therapeutics worth $310K as of Q3 2026.
  • CAP Partners bought 380 CRISPR Therapeutics shares in Q3 2026, an estimated $20.5K.
  • CRISPR Therapeutics made up 0.14% of CAP Partners's portfolio in Q3 2026, its #124 holding.
  • CAP Partners first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 413 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on CAP Partners's 13F filing for Q3 2026, filed 19 Oct 2026.